Access Restriction

Author Liu, Jibing ♦ Yan, Jingchen ♦ Zhou, Changchun ♦ Ma, Qinghua ♦ Jin, Qingyan ♦ Yang, Zhenbin
Source SpringerLink
Content type Text
Publisher Springer Netherlands
File Format PDF
Copyright Year ©2014
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword miR-1285-3p ♦ JUN ♦ Plasma ♦ HCC ♦ TACE ♦ Prognosis ♦ Cancer Research
Abstract In the world, hepatocellular carcinoma (HCC) is one of the most common and most lethal cancers. Currently, standard therapy for unresectable HCC is a local–regional therapy with transarterial chemoembolisation (TACE). In this study, we sought to assess whether plasma circulating microRNAs (miRNAs) can be used to predict the prognosis of HCC patients receiving the TACE treatment. Firstly, we systematically examined TACE therapeutic effectiveness-related circulating miRNAs through miRNA Profiling Chips. As a result, we identified 19 circulating miRNAs to be significantly differentially expressed between the TACE-response group and the TACE-nonresponse group. In the second stage, we performed quantitative analyses of these candidate miRNAs in additional HCC patients treated with TACE and validated two of the aforementioned 19 miRNAs (miR-1285-3p and miR-4741) as candidate biomarkers for predicting prognosis of TACE. Interestingly, we found that miR-1285-3p could directly repress JUN oncogene expression in HCC cells, indicating miR-1285-3p could act as a potential tumor suppressor. In conclusion, our data indicate that circulating miR-1285-3p and miR-4741 was predictive of response to TACE therapy in HCC.
ISSN 10104283
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2014-09-18
Publisher Place Dordrecht
e-ISSN 14230380
Journal Tumor Biology
Volume Number 36
Issue Number 1
Page Count 7
Starting Page 219
Ending Page 225

Open content in new tab

   Open content in new tab
Source: SpringerLink